

# Mohamed A Ebrahim

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8974727/publications.pdf>

Version: 2024-02-01

31  
papers

360  
citations

840119

11  
h-index

794141

19  
g-index

31  
all docs

31  
docs citations

31  
times ranked

705  
citing authors

#	ARTICLE	IF	CITATIONS
1	Chemopreventive and hepatoprotective effects of Epigallocatechin-gallate against hepatocellular carcinoma: role of heparan sulfate proteoglycans pathway. <i>Journal of Pharmacy and Pharmacology</i> , 2014, 66, 1032-1045.	1.2	39
2	Hepatoprotective and anti-tumor effects of targeting MMP-9 in hepatocellular carcinoma and its relation to vascular invasion markers. <i>Clinical and Experimental Metastasis</i> , 2015, 32, 479-493.	1.7	37
3	Relevance of Serum Levels of Interleukin-6 and Syndecan-1 in Patients with Hepatocellular Carcinoma. <i>Scientia Pharmaceutica</i> , 2012, 80, 179-188.	0.7	34
4	Suramin inhibits hepatic tissue damage in hepatocellular carcinoma through deactivation of heparanase enzyme. <i>European Journal of Pharmacology</i> , 2014, 728, 151-160.	1.7	31
5	Association of MDR1 gene polymorphism (G2677T) with imatinib response in Egyptian chronic myeloid leukemia patients. <i>Hematology</i> , 2014, 19, 123-128.	0.7	29
6	Breast cancer characteristics in very young Egyptian women &le;35 years. <i>Breast Cancer: Targets and Therapy</i> , 2016, 8, 53.	1.0	21
7	Validity of Osteoprotegerin and Receptor Activator of NF- $\kappa$ B Ligand for the Detection of Bone Metastasis in Breast Cancer. <i>Oncology Research</i> , 2017, 25, 641-650.	0.6	19
8	Galectin-3 and matrix metalloproteinase-9: Perspective in management of hepatocellular carcinoma. <i>Journal of Oncology Pharmacy Practice</i> , 2015, 21, 323-330.	0.5	18
9	Evaluation of antiglypican-3 therapy as a promising target for amelioration of hepatic tissue damage in hepatocellular carcinoma. <i>European Journal of Pharmacology</i> , 2015, 746, 353-362.	1.7	17
10	Chemopreventive and hepatoprotective effects of genistein via inhibition of oxidative stress and the versican/PDGF/PKC signaling pathway in experimentally induced hepatocellular carcinoma in rats by thioacetamide. <i>Redox Report</i> , 2022, 27, 9-20.	1.4	17
11	Clinical significance of the TNF- $\alpha$ receptors, TNFRSF2 and TNFRSF9, on cell migration molecules Fascin-1 and Versican in acute leukemia. <i>Cytokine</i> , 2018, 111, 523-529.	1.4	13
12	Fucoidan Ameliorates Hepatocellular Carcinoma Induced in Rats: Effect on miR143 and Inflammation. <i>Nutrition and Cancer</i> , 2021, 73, 1498-1510.	0.9	13
13	Nitric Oxide is a Potential Diagnostic Marker for Hepatocellular Carcinoma. <i>Scientia Pharmaceutica</i> , 2013, 81, 763-775.	0.7	11
14	Prognostic value of lymph node ratio in node-positive breast cancer in Egyptian patients. <i>Journal of the Egyptian National Cancer Institute</i> , 2014, 26, 31-35.	0.6	11
15	64 multidetector CT findings of influenza A (H1N1) virus in patients with hematologic malignancies. <i>Acta Radiologica</i> , 2012, 53, 662-667.	0.5	10
16	Clinical outcome of HCV-positive patients with diffuse large B-cell lymphoma treated with rituximab-based chemotherapy. <i>Annals of Hematology</i> , 2014, 93, 1903-1911.	0.8	9
17	Phase II study of capecitabine plus cisplatin in patients with gastric cancer. <i>Anti-Cancer Drugs</i> , 2009, 20, 191-196.	0.7	4
18	Circulating adiponectin: a potential prognostic marker for hepatocellular carcinoma. <i>Chinese-German Journal of Clinical Oncology</i> , 2011, 10, 570-574.	0.1	4

#	ARTICLE	IF	CITATIONS
19	A Phase II Study of Outpatient Biweekly Gemcitabine-Oxaliplatin in Advanced Biliary Tract Carcinomas. Japanese Journal of Clinical Oncology, 2011, 41, 217-224.	0.6	4
20	Measuring serum levels of glycosaminoglycans for prediction and using viscum fraxini-2 for treatment of patients with hepatocellular carcinoma. Journal of Pharmacy Research, 2013, 7, 571-575.	0.4	4
21	Cytotoxic effects of suramin against HepG2 cells through activation of intrinsic apoptotic pathway. Journal of B U on, 2014, 19, 1048-54.	0.4	4
22	Short Dysfunctional Telomere is Highly Predictive of Dismal Outcome in MDS but Not in AML Patients. International Journal of Hematology-Oncology and Stem Cell Research, 2020, 14, 188-199.	0.3	3
23	TERT Genotype Polymorphism: A Glance of Change Egyptian MDS Outcomes. Asian Pacific Journal of Cancer Prevention, 2021, 22, 1547-1555.	0.5	2
24	Dickkopf-1 and Amphiregulin as Novel Biomarkers and Potential Therapeutic Targets in Hepatocellular Carcinoma. International Journal of Hematology-Oncology and Stem Cell Research, 2019, 13, 153-163.	0.3	2
25	Leukemia propagating cells in Philadelphia chromosome-positive ALL: a resistant phenotype with an adverse prognosis. Blood Research, 2018, 53, 138.	0.5	1
26	The 6 Month Nightmare. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, S249.	0.2	1
27	Evaluation of the Diagnostic and Prognostic Value of Syndecan-1 in Acute Leukemia Patients. Cureus, 2020, 12, e10594.	0.2	1
28	Case report; meta-synchronous triple malignancy in primary diagnosed CML patient. American Journal of Blood Research, 2020, 10, 22-25.	0.6	1
29	Thioredoxin-1 and MMP-9 as biomarkers in breast cancer metastasis in Egyptian female patients. Egyptian Journal of Basic and Applied Sciences, 2018, 5, 63-68.	0.2	0
30	Clinico-Epidemiological Study on Acute Promyelocytic Leukemia Among Egyptian Patients. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, S223-S224.	0.2	0
31	Multiple Myeloma in HCV Infected Patients is Associated with Therapy Resistance and Adverse Prognosis with No Distinct Clinicopathologic Features. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, S330.	0.2	0